Sumoylation Inhibits the Growth Suppressive Properties of Ikaros

PLoS One. 2016 Jun 17;11(6):e0157767. doi: 10.1371/journal.pone.0157767. eCollection 2016.

Abstract

The Ikaros transcription factor is a tumor suppressor that is also important for lymphocyte development. How post-translational modifications influence Ikaros function remains partially understood. We show that Ikaros undergoes sumoylation in developing T cells that correspond to mono-, bi- or poly-sumoylation by SUMO1 and/or SUMO2/3 on three lysine residues (K58, K240 and K425). Sumoylation occurs in the nucleus and requires DNA binding by Ikaros. Sumoylated Ikaros is less effective than unsumoylated forms at inhibiting the expansion of murine leukemic cells, and Ikaros sumoylation is abundant in human B-cell acute lymphoblastic leukemic cells, but not in healthy peripheral blood leukocytes. Our results suggest that sumoylation may be important in modulating the tumor suppressor function of Ikaros.

MeSH terms

  • Animals
  • B-Lymphocytes / pathology
  • Cell Line, Tumor
  • DNA-Binding Proteins / biosynthesis
  • DNA-Binding Proteins / genetics*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Ikaros Transcription Factor / biosynthesis
  • Ikaros Transcription Factor / genetics*
  • Lymphocytes / pathology
  • Mice
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Protein Processing, Post-Translational / genetics
  • SUMO-1 Protein / genetics
  • Sumoylation / genetics
  • Transcription, Genetic*
  • Tumor Suppressor Proteins

Substances

  • DNA-Binding Proteins
  • SUMO-1 Protein
  • SUMO1 protein, human
  • Tumor Suppressor Proteins
  • Ikaros Transcription Factor

Grants and funding

This work was supported by the Agence Nationale de la Recherche (ANR-11-BSV3-018), the Ligue Nationale contre le Cancer (équipe labellisée 2006-2012 and 2015-2017), the Conférence de Coordination Inter-Régionale du Grand-Est of the Ligue contre le Cancer (#173AC.2012 to PK) and institutional funds from INSERM, CNRS, University of Strasbourg and the ANR-10-LABX-0030-INRT grant. A.A. received a pre-doctoral fellowship from the Ministry of Research and Technology. I.L-M. received a post-doctoral fellowship from the Fondation ARC. A.O. received post-doctoral fellowships from the Institut National du Cancer and the Fondation pour la Recherche Médicale.